The FDA has declared it a "public health crisis waiting to happen" and has issued a warning to a Florida manufacturer to pull its nicotine-laced gummies off the market. The incident is notable because few people were aware of the product's existence prior to the FDA's announcement, including news releases, Twitter posts and social media attaboy posts from tobacco control organizations such as Truth Initiative. Gregory Conley, president of the American Vaping Association, tweeted, "The FDA has just cancelled a product used by 23 Americans on a regular basis." "The long, legendary history of tobacco control has been to distract attention with shiny new objects while cigarettes continue to be sold.
Krave Nic, a soft candy manufacturer based in Florida, has been cited by the FDA for selling candy containing synthetic nicotine without submitting a premarket tobacco application (PMTA) or obtaining marketing authorization from the agency. Earlier this year, the FDA received authorization over synthetic nicotine, and since July 14th, selling any products with synthetic nicotine without authorization is technically illegal. The warning letter includes a comprehensive press release from the FDA's Center for Tobacco Products, featuring quotes from FDA Commissioner Robert Califf and CTP Director Brian King, suggesting that nicotine candy may pose a serious public health threat.
We remain firmly committed to using regulatory and law enforcement resources to curb all illegal marketing of tobacco products, especially those that are easily confused with items consumed frequently by young people, such as candy," said Gold. According to the FDA, Krave's nicotine gum (which contains 1 milligram of nicotine per box, with 12 pieces per box) poses a significant risk to children. "Studies have shown that ingestion of 1 to 4 milligrams of nicotine, depending on the child's weight, can cause severe toxicity in children under six," the press release said. "However, nicotine poisoning in young people of any age can lead to nausea, vomiting, stomach pain, increased blood pressure and heart rate, seizures, respiratory failure, coma and even death.
The FDA has approved nicotine gum and lozenges that are produced by pharmaceutical companies and sold over-the-counter. These products contain more nicotine than Krave gum and have appealing flavors. They are sold in large quantities and available in tens of thousands of stores nationwide. "Nicotine gum is a public health crisis waiting to happen among our young people, especially as we enter a new school year," said Califf. "We want parents to understand these products and the potential health consequences for children of all ages, including the toxicity to toddlers and the allure of these addictive products to our young people. When illicit products enter the market, the FDA will not sit idly by.
This statement is a prime example of an institution that goes too far in its efforts to be correct, losing all sense of purpose and proportionality, and now flailing in the shadows. As we have explained, when faced with external pressure, the FDA often attacks insignificant threats with absurd ferocity.
Today's action should serve as a wake-up call to the manufacturers of these illegal products, and the FDA is actively working to investigate any wrongdoing and seek corrective measures," said CTP Director King. The warning letter gives Krave Nic 15 working days to respond, "describing the actions taken to address any violations and bring your products into compliance." According to Krave's website, this should not be difficult as these products have already been discontinued. It is unclear at this time whether these gummies were eliminated due to the FDA's letter or a lack of retail interest.
Statement
This article is compiled from third-party information and is intended solely for industry exchange and learning.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content. The translation of this article is only intended for industry communication and research purposes.
Due to limitations in our translating ability, the translated article may not fully express the same meaning as the original text. Therefore, please refer to the original text for accuracy.
In regards to any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions, 2FIRSTS maintains complete alignment with the Chinese government.
The compilation of information is owned by the original media and authors. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
